Alex MacKenzie
Children's Hospital of Eastern Ontario
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alex MacKenzie.
Immunity | 2008
Jenny P.-Y. Ting; Ruth C. Lovering; Emad S. Alnemri; John Bertin; Jeremy M. Boss; Beckley K. Davis; Richard A. Flavell; Stephen E. Girardin; Adam Godzik; Jonathan A. Harton; Hal M. Hoffman; Jean Pierre Hugot; Naohiro Inohara; Alex MacKenzie; Lois J. Maltais; Gabriel Núñez; Yasunori Ogura; Luc A. Otten; Dana J. Philpott; John C. Reed; Walter Reith; Stefan Schreiber; Viktor Steimle; Peter A. Ward
Iimmune regulatory proteins such as CIITA, NAIP, IPAF, NOD1, NOD2, NALP1, cryopyrin/NALP3 are members of a family characterized by the presence of a nucleotide-binding domain (NBD) and leucine-rich repeats (LRR). Members of this gene family encode a protein structure similar to the NB-LRR subgroup of disease-resistance genes in plants and are involved in the sensing of pathogenic products and the regulation of cell signaling and apoptosis. Several members of this family have been associated with immunologic disorders. NOD2 for instance is associated with both Crohns disease and Blau syndrome. A variety of different names are currently used to describe this gene family, its subfamilies and individual genes, including CATERPILLER (CLR), NOD-LRR, NACHT-LRR, CARD, NALP, NOD, PAN and PYPAF, and this lack of consistency has led to a pressing need to unify the nomenclature. Consequently, we collectively propose the family designation NLR (nucleotide-binding domain and leucine-rich repeat containing) and provide unique and standardized gene designations for all family members.
Immunity | 2008
Jenny P.-Y. Ting; Ruth C. Lovering; Emad S. Alnemri; John Bertin; Jeremy M. Boss; Beckley K. Davis; Richard A. Flavell; Stephen E. Girardin; Adam Godzik; Jonathan A. Harton; Hal M. Hoffman; Jean-Pierre Hugot; Naohiro Inohara; Alex MacKenzie; Lois J. Maltais; Gabriel Núñez; Yasunori Ogura; Luc A. Otten; Peter A. Ward
Iimmune regulatory proteins such as CIITA, NAIP, IPAF, NOD1, NOD2, NALP1, cryopyrin/NALP3 are members of a family characterized by the presence of a nucleotide-binding domain (NBD) and leucine-rich repeats (LRR). Members of this gene family encode a protein structure similar to the NB-LRR subgroup of disease-resistance genes in plants and are involved in the sensing of pathogenic products and the regulation of cell signaling and apoptosis. Several members of this family have been associated with immunologic disorders. NOD2 for instance is associated with both Crohns disease and Blau syndrome. A variety of different names are currently used to describe this gene family, its subfamilies and individual genes, including CATERPILLER (CLR), NOD-LRR, NACHT-LRR, CARD, NALP, NOD, PAN and PYPAF, and this lack of consistency has led to a pressing need to unify the nomenclature. Consequently, we collectively propose the family designation NLR (nucleotide-binding domain and leucine-rich repeat containing) and provide unique and standardized gene designations for all family members.
Nature Medicine | 1997
Daigen Xu; Stephen J. Crocker; J.-P. Doucet; M. St-Jean; K. Tamai; A.M. Hakim; J.-E. Ikeda; Peter Liston; Charlie S. Thompson; Robert G. Korneluk; Alex MacKenzie; George S. Robertson
We show here that transient forebrain ischemia selectively elevates levels of neuronal apoptosis inhibitory protein (NAIP) in rat neurons that are resistant to the injurious effects of this treatment. This observation suggests that increasing NAIP levels may confer protection against ischemic cell death. Consistent with this proposal, we demonstrate that two other treatments that increase neuronal NAIP levels, systemic administration of the bacterial alkaloid K2S2a and intracerebral injection of an adenovirus vector capable of overexpressing NAIP in vivo, reduce ischemic damage in the rat hippocampus. Taken together, these findings suggest that NAIP may play a key role in conferring resistance to ischemic damage and that treatments that elevate neuronal levels of this antiapoptotic protein may have utility in the treatment of stroke.
American Journal of Medical Genetics | 1996
Rhiannon Hughes-Benzie; J.Y. Xuan; Alasdair G. W. Hunter; Emily Chen; Mahin Golabi; J.A. Hurst; J. Kobori; K. Marymee; Pagon Ra; H.H. Punnett; Susan Schelley; J.L. Tolmie; Monica M. Wohlferd; T. Grossman; D. Schlessinger; Alex MacKenzie
Simpson-Golabi-Behmel syndrome (SGBS) is an X-linked overgrowth disorder recently shown to be caused by mutations in the heparan sulfate proteoglycan GPC3 [Pilia et al., Nat Genet; 12:241-247 1996]. We have used Southern blot analysis and polymerase chain reaction amplification of intra-exonic sequences to identify four new GPC3 mutations and further characterize three previously reported SGBS mutations. De novo GPC3 mutations were identified in 2 families. In general, the mutations were unique deletions ranging from less than 0.1 kb to more than 300 kb in length with no evidence of a mutational hot spot discerned. The lack of correlation between the phenotype of 18 affected males from these 7 families and the location and size of the GPC3 gene mutations suggest that SGBS is caused by a nonfunctional GPC3 protein.
European Journal of Neuroscience | 2000
Daniel Perrelet; A. Ferri; Alex MacKenzie; G. M. Smith; Robert G. Korneluk; Peter Liston; Y. Sagot; J. Terrado; D. Monnier; Ann C. Kato
Neuronal apoptosis inhibitory protein (NAIP), and human inhibitors of apoptosis 1 and 2 (HIAP1 and HIAP2) are three members of the mammalian family of antiapoptosis proteins called ‘inhibitors of apoptosis’ (IAP). These molecules can prevent apoptosis in vitro and the over‐expression of NAIP can decrease ischemic damage in the hippocampus. The goal of our experiments was to determine whether administration of NAIP, HIAP1 and HAIP2 could rescue motoneurons following axotomy of a peripheral nerve. In young rats, an adenoviral gene transfer technique was used to deliver and express these proteins in motoneurons; a fluorescent tracer was simultaneously added as a means for quantitatively assessing the rescue of fluorescently labelled motoneurons in serial sections of the lumbar spinal cord. Control experiments using adenoviral vectors (adv) expressing the lacZ gene showed that 14% of the sciatic motoneuron pool could be transfected indicating the existence of a subpopulation of spinal motoneurons susceptible to this class of viral vectors. The administration of an adv‐NAIP, adv‐HIAP1 and adv‐HIAP2 rescued 30–40% of motoneurons at one week after sciatic axotomy. The efficiency of these proteins was similar to that of two neurotrophic factors, ciliary neurotrophic factor and brain‐derived neurotrophic factor, administrated by the same viral technique. The effect of the IAP proteins on motoneuron survival decreased with time but was still present after 4 weeks postaxotomy; the duration of the response was dependent upon the viral titre. These experiments demonstrate that IAP family proteins can prevent motoneuron cell death in vivo and may offer a new therapeutic approach for motoneuron diseases.
European Journal of Neuroscience | 2001
Stephen J. Crocker; Nichola Wigle; Peter Liston; Charlie S. Thompson; Christopher J. Lee; Daigen Xu; Sophie Roy; Donald W. Nicholson; David S. Park; Alex MacKenzie; Robert G. Korneluk; George S. Robertson
Parkinsons disease (PD) is a progressive neurodegenerative disorder of the basal ganglia, associated with the inappropriate death of dopaminergic neurons of the substantia nigra pars compacta (SNc). Here, we show that adenovirally mediated expression of neuronal apoptosis inhibitor protein (NAIP) ameliorates the loss of nigrostriatal function following intrastriatal 6‐OHDA administration by attenuating the death of dopamine neurons and dopaminergic fibres in the striatum. In addition, we also addressed the role of the cysteine protease caspase‐3 activity in this adult 6‐OHDA model, because a role for caspases has been implicated in the loss of dopamine neurons in PD, and because NAIP is also a reputed inhibitor of caspase‐3. Although caspase‐3‐like proteolysis was induced in the SNc dopamine neurons of juvenile rats lesioned with 6‐OHDA and in adult rats following axotomy of the medial forebrain bundle, caspase‐3 is not induced in the dopamine neurons of adult 6‐OHDA‐lesioned animals. Taken together, these results suggest that therapeutic strategies based on NAIP may have potential value for the treatment of PD.
The Journal of Comparative Neurology | 1997
D.G. Xu; Robert G. Korneluk; K. Tamai; N. Wigle; A. Hakim; Alex MacKenzie; George S. Robertson
We have recently shown that spinal muscular atrophy (SMA), an autosomal recessive disorder characterized by motor neuron loss, is associated with deletion of a gene that encodes the neuronal apoptosis inhibitory protein (NAIP). In the present study, we have examined the distribution of NAIP‐like immunoreactivity (NAIP‐LI) in the rat central nervous system (CNS) by using an affinity‐purified polyclonal antibody against NAIP. In the forebrain, immunoreactive neurons were detected in the cortex, the hippocampus (pyramidal cells, dentate granule cells, and interneurons), the striatum (cholinergic interneurons), the basal forebrain (ventral pallidum, medial septal nucleus, and diagonal band), the thalamus (lateral and ventral nuclei), the habenula, the globus pallidus, and the entopenduncular nucleus. In the midbrain, NAIP‐LI was located primarily within neurons of the red nucleus, the substantia nigra pars compacta, the oculomotor nucleus, and the trochlear nucleus. In the brainstem, neurons containing NAIP‐LI were observed in cranial nerve nuclei (trigeminal, facial, vestibular, cochlear, vagus, and hypoglossal nerves) and in relay nuclei (pontine, olivary, lateral reticular, cuneate, gracile nucleus, and locus coeruleus). In the cerebellum, NAIP‐LI was found within both Purkinje and nuclear cells (interposed and lateral nuclei). Finally, within the spinal cord, NAIP‐LI was detected in Clarkes column and in motor neurons. Taken together, these results indicate that NAIP‐LI is distributed broadly in the CNS. However, high levels of NAIP‐LI were restricted to those neuronal populations that have been reported to degenerate in SMA. This anatomical correspondence provides additional evidence for NAIP involvement in the neurodegeneration observed in acute SMA. J. Comp. Neurol. 382:247‐259, 1997.
Human Genetics | 1989
Han G. Brunner; Robert G. Korneluk; M. Coerwinkel-Driessen; Alex MacKenzie; H. Smeets; H.M.M. Lambermon; B.A. van Oost; Bé Wieringa; H. H. Ropers
SummaryWe have studied genetic linkage between the gene for creatine kinase muscle type (CKMM) and the gene for myotonic dystrophy (DM). In a panel of 65 myotonic dystrophy families from Canada and the Netherlands, a maximum lod score (Zmax) of 22.8 at a recombination frequency (Θ) of 0.03 was obtained. Tight linkage was also demonstrated for CKMM and the gene for apolipoprotein C2 (ApoC2). This establishes CKMM as a useful marker for myotonic dystrophy.
Genomics | 1989
Robert G. Korneluk; Alex MacKenzie; Yusuke Nakamura; I. Dubé; Pierre Jacob; Alasdair G. W. Hunter
The gene for myotonic dystrophy (DM), the most common form of adult muscular dystrophy, has previously been mapped to the proximal long arm of chromosome 19. We have conducted linkage analysis on 53 DM families (comprising 421 individuals) using seven DM-linked DNA markers. This analysis, combined with our somatic cell hybrid mapping panel data, places the DM locus more distal on the chromosome 19 long arm than previously thought. Further, we have been able to unequivocally identify DNA markers that flank the disease locus. The definition of a 10-cM region of chromosome 19 that contains the DM locus should prove useful in both the search for the causative gene and the molecular diagnosis of DM.
Orphanet Journal of Rare Diseases | 2012
Hugh J. McMillan; Thea Worthylake; Jeremy Schwartzentruber; Chloe Gottlieb; Sarah Lawrence; Alex MacKenzie; Chandree L. Beaulieu; Petra A. W. Mooyer; Jacek Majewski; Dennis E. Bulman; Michael T. Geraghty; Sacha Ferdinandusse; Kym M. Boycott
BackgroundD-bifunctional protein (DBP) deficiency is typically apparent within the first month of life with most infants demonstrating hypotonia, psychomotor delay and seizures. Few children survive beyond two years of age. Among patients with prolonged survival all demonstrate severe gross motor delay, absent language development, and severe hearing and visual impairment. DBP contains three catalytically active domains; an N-terminal dehydrogenase, a central hydratase and a C-terminal sterol carrier protein-2-like domain. Three subtypes of the disease are identified based upon the domain affected; DBP type I results from a combined deficiency of dehydrogenase and hydratase activity; DBP type II from isolated hydratase deficiency and DBP type III from isolated dehydrogenase deficiency. Here we report two brothers (16½ and 14 years old) with DBP deficiency characterized by normal early childhood followed by sensorineural hearing loss, progressive cerebellar and sensory ataxia and subclinical retinitis pigmentosa.Methods and resultsBiochemical analysis revealed normal levels of plasma VLCFA, phytanic acid and pristanic acid, and normal bile acids in urine; based on these results no diagnosis was made. Exome analysis was performed using the Agilent SureSelect 50Mb All Exon Kit and the Illumina HiSeq 2000 next-generation-sequencing (NGS) platform. Compound heterozygous mutations were identified by exome sequencing and confirmed by Sanger sequencing within the dehydrogenase domain (c.101C>T; p.Ala34Val) and hydratase domain (c.1547T>C; p.Ile516Thr) of the 17β-hydroxysteroid dehydrogenase type 4 gene (HSD17B4). These mutations have been previously reported in patients with severe-forms of DBP deficiency, however each mutation was reported in combination with another mutation affecting the same domain. Subsequent studies in fibroblasts revealed normal VLCFA levels, normal C26:0 but reduced pristanic acid beta-oxidation activity. Both DBP hydratase and dehydrogenase activity were markedly decreased but detectable.ConclusionsWe propose that the DBP phenotype seen in this family represents a distinct and novel subtype of DBP deficiency, which we have termed type IV based on the presence of a missense mutation in each of the domains of DBP resulting in markedly reduced but detectable hydratase and dehydrogenase activity of DBP. Given that the biochemical testing in plasma was normal in these patients, this is likely an underdiagnosed form of DBP deficiency.